Inhibrx Biosciences, Inc.
INBX
$29.59
$0.4851.67%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.30M | -- | 100.00K | -- | 100.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.30M | -- | 100.00K | -- | 100.00K |
| Cost of Revenue | 1.58M | 1.26M | 33.37M | 38.89M | 29.22M |
| Gross Profit | -282.00K | -1.26M | -33.27M | -38.89M | -29.12M |
| SG&A Expenses | 6.42M | 6.02M | -51.40M | 7.90M | 93.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.69M | 42.90M | -18.03M | 46.80M | 161.00M |
| Operating Income | -27.39M | -42.90M | 18.13M | -46.80M | -160.90M |
| Income Before Tax | -28.65M | -43.31M | -47.87M | -43.86M | 1.86B |
| Income Tax Expenses | 2.00K | -- | 0.00 | -- | 2.00K |
| Earnings from Continuing Operations | -28.65M | -43.31M | -47.87M | -43.86M | 1.86B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.65M | -43.31M | -47.87M | -43.86M | 1.86B |
| EBIT | -27.39M | -42.90M | 18.13M | -46.80M | -160.90M |
| EBITDA | -26.73M | -42.23M | 18.82M | -46.04M | -160.42M |
| EPS Basic | -1.85 | -2.80 | -3.09 | -2.84 | 127.10 |
| Normalized Basic EPS | -1.16 | -1.75 | 0.82 | -1.77 | -6.99 |
| EPS Diluted | -1.85 | -2.80 | -3.10 | -2.84 | 125.48 |
| Normalized Diluted EPS | -1.16 | -1.75 | 0.82 | -1.77 | -6.90 |
| Average Basic Shares Outstanding | 15.47M | 15.47M | 15.47M | 15.47M | 14.62M |
| Average Diluted Shares Outstanding | 15.47M | 15.47M | 15.47M | 15.47M | 14.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |